- Report
- February 2026
Global
From €600EUR$740USD£540GBP
- Report
- February 2026
Global
From €450EUR$555USD£405GBP
- Report
- February 2026
Global
From €750EUR$924USD£676GBP
- Report
- February 2026
Global
From €600EUR$740USD£540GBP
- Report
- February 2026
Global
From €450EUR$555USD£405GBP
- Report
- February 2026
Global
From €300EUR$370USD£270GBP
- Report
- February 2026
Global
From €450EUR$555USD£405GBP
- Report
- February 2026
Global
From €300EUR$370USD£270GBP
- Report
- February 2026
Global
From €300EUR$370USD£270GBP
- Report
- February 2026
Global
From €300EUR$370USD£270GBP
- Report
- February 2026
Global
From €200EUR$247USD£180GBP
- Report
- March 2025
- 84 Pages
Global
From €400EUR$493USD£360GBP
- Report
- August 2023
- 267 Pages
Global
From €2150EUR$2,650USD£1,937GBP
- Report
- June 2022
- 115 Pages
Global
From €1050EUR$1,294USD£946GBP
- Report
- May 2022
- 50 Pages
Global
From €500EUR$616USD£450GBP
- Report
- May 2022
- 32 Pages
Global
From €400EUR$493USD£360GBP
- Report
- October 2021
- 433 Pages
Global
From €2250EUR$2,773USD£2,027GBP
- Report
- July 2021
- 259 Pages
Global
From €2150EUR$2,650USD£1,937GBP
- Report
- December 2023
- 307 Pages
Global
From €4302EUR$4,950USD£3,744GBP
- Report
- October 2023
- 273 Pages
Global
From €4302EUR$4,950USD£3,744GBP

The Antibody Drug market is a subset of the biotechnology industry that focuses on the development and commercialization of therapeutic antibodies. Antibody drugs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. These drugs are designed to target specific molecules in the body, such as proteins, hormones, and enzymes, and can be used to block or activate certain pathways. Antibody drugs are typically administered intravenously or subcutaneously, and can be used in combination with other drugs or therapies.
The Antibody Drug market is highly competitive, with many companies investing in research and development to create new and improved treatments. Companies in the market are focused on developing novel antibodies, as well as improving existing treatments. Additionally, companies are investing in the development of biosimilars, which are generic versions of existing antibody drugs.
Some companies in the Antibody Drug market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, Regeneron, Roche, and Sanofi. Show Less Read more